Sapiens (SPNS) Announces $100M Proposed Public Offering of its Common Shares

Sapiens International Corporation N.V. (Nasdaq: SPNS) (TASE: SPNS) ("Sapiens"), a leading global provider of software solutions for the insurance industry, announced today the commencement of a proposed underwritten public offering of $100.0 million of its common shares. Sapiens intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of its common shares. All of the shares in the proposed offering are to be sold by Sapiens.

Sapiens intends to use the net proceeds from the proposed offering for general corporate purposes, which may include, among other things, acquisitions or investments in companies, products or technologies and additions to working capital. However, Sapiens has not entered into any agreements for, or otherwise committed to, any specific acquisitions at this time.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Jefferies LLC are acting as the representatives of the underwriters and as joint book-running managers for the proposed offering. Needham & Company, LLC and William Blair & Company, L.L.C. are acting as co-managers for the proposed offering.

The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

The securities described above are being offered solely pursuant to an effective shelf registration statement (including a prospectus) that was filed with the U.S. Securities and Exchange Commission (the "SEC") on July 11, 2019. This offering will be made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement.

Before you invest, you should read the prospectus included in the registration statement, the preliminary prospectus supplement and the other documents Sapiens has filed or will file with the Securities and Exchange Commission (the "SEC") for more complete information about Sapiens and the proposed offering.

You May Also Be Interested In

• Andersen closes secondary offering of 4.9M shares at $44 each
• Aveanna selling stockholders launch 15M share secondary offering
• Gossamer Bio raises up to $250M in private placement for PAH drug